Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—The Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, New York City, have adopted Qiagen’s Ingenuity Variant Analysis solution for research and translational genomics applications related to characterizing and identifying rare diseases.
February 2014—Telcor’s QML point-of-care software solution now provides connectivity for the Sofia fluorescent immunoassay analyzer.
February 2014—Applied Spectral Imaging (ASI) and Biocare Medical signed a partnership agreement in which Biocare will distribute ASI’s IHC and CISH imaging and analysis solution, GenASIs Pathology, in the United States. The agreement brings to cytopathology and anatomic pathology laboratories a fully integrated solution that improves quality while providing workflow efficiencies.
February 2014—To meet the needs of today’s next-generation sequencing projects, Aurora Biomed offers the VERSA NGS Library Prep Workstation for high throughput preparation of sample libraries. VERSA enables automated processing of up to 96 libraries in parallel with the high precision needed for quality results.
February 2014—Myriad Genetics announced a research collaboration with BioMarin that will use Myriad’s novel HRD (homologous recombination deficiency) test to identify tumor types that may be sensitive to BioMarin’s investigational product candidate, BMN-673. Specific terms of the deal, the second research collaboration between the partners, were not disclosed.
February 2014—Hamilton Scientific recently completed installation of 60 fume hoods and 120 laboratory benches in the 200,000-sq.-ft. lab space at the Wisconsin Energy Institute and Consolidated Forensic Lab. The laboratory workstation design was developed in response to the customer’s request for ease of utility access while simultaneously allowing for movable laboratory benches.
February 2014—TissueMark, developed by Belfast-based digital pathology specialists PathXL, was launched at the 2013 annual meeting of the Association for Molecular Pathology. It analyzes the structural patterns in tissue samples and marks the boundaries of potentially cancerous sections for more detailed analysis.
February 2014—Empirical Bioscience, a company that produces high-grade PCR reagents and enzymes, has introduced rEVAlution qPCR Master Mix, an environmentally safe, ready-to-use hot start qPCR mixture specifically formulated with high-quality components to offer superior safety, speed, and signaling capabilities.
February 2014—Integrated DNA Technologies launched the latest addition to its portfolio of next-generation sequencing products, xGen Universal Blocking Oligos. By incorporating these oligos into target-capture experiments, users can decrease the complexity and increase the throughput of their target-capture experiment without degrading performance.
February 2014—OraSure Technologies has reached an agreement with Thermo Fisher Scientific to develop and supply up to 12 homogenous, fully automated oral fluid drugs-of-abuse assays to be used with OraSure’s new Intercept oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and certain foreign countries, subject to receipt of applicable regulatory approvals.
